Compassionate access to virus-specific T cells for adoptive immunotherapy over 15 years

Neller, MA; Ambalathingal, GR; Hamad, N; Sasadeusz, J; Pearson, R; Holmes-Liew, CL; Singhal, D; Tunbridge, M; Ng, WY; Sharplin, K; Moore, A; Deambrosis, D; Soosay-Raj, T; McNaughton, P; Whyte, M; Fraser, C; Grigg, A; Kliman, D; Bajel, A; Cummins, K; Dowling, M; Yeoh, ZH; Harrison, SJ; Khot, A; Tan, S; Roos, I; Koo, RM; Dohrmann, S; Ritchie, D; Wainstein, B; McCleary, K; Nelson, A; Gardiner, B; Inam, S; Badoux, X; Ma, K; Toro, C; Hanna, D; Hughes, D; Conyers, R; Cole, T; Wang, SS; Chee, L; Fleming, J; Irish, A; Purtill, D; Cooney, J; Shaw, P; Tey, SK; Hunt, S; Subramonia Pillai, E; John, G; Ng, M; Ramachandran, S; Hopkins, P; Chambers, D; Campbell, S; Francis, R; Isbel, N; Marlton, P; Reddiex, H; Matthews, KK; Voogt, M; Panikkar, A; Beagley, L; Rehan, S; Best, S; Raju, J; Le Texier, L; Crooks, P; Solomon, M; Lekieffre, L; Srihari, S; Smith, C; Khanna, R

Author(s): Neller, MA; Ambalathingal, GR; Hamad, N; Sasadeusz, J; Pearson, R; Holmes-Liew, CL; Singhal, D; Tunbridge, M; Ng, WY; Sharplin, K; Moore, A; Deambrosis, D; Soosay-Raj, T; McNaughton, P; Whyte, M; Fraser, C; Grigg, A; Kliman, D; Bajel, A; Cummins, K; Dowling, M; Yeoh, ZH; Harrison, SJ; Khot, A; Tan, S; Roos, I; Koo, RM; Dohrmann, S; Ritchie, D; Wainstein, B; McCleary, K; Nelson, A; Gardiner, B; Inam, S; Badoux, X; Ma, K; Toro, C; Hanna, D; Hughes, D; Conyers, R; Cole, T; Wang, SS; Chee, L; Fleming, J; Irish, A; Purtill, D; Cooney, J; Shaw, P; Tey, SK; Hunt, S; Subramonia Pillai, E; John, G; Ng, M; Ramachandran, S; Hopkins, P; Chambers, D; Campbell, S; Francis, R; Isbel, N; Marlton, P; Reddiex, H; Matthews, KK; Voogt, M; Panikkar, A; Beagley, L; Rehan, S; Best, S; Raju, J; Le Texier, L; Crooks, P; Solomon, M; Lekieffre, L; Srihari, S; Smith, C; Khanna, R;
Details: Publication Year 2024-12-03,Volume 15,Issue #1,Page 10339
Journal Title: Nature Communications
Publication Type: Research article
Abstract: Adoptive T-cell immunotherapy holds great promise for the treatment of viral complications in immunocompromised patients resistant to standard anti-viral strategies. We present a retrospective analysis of 78 patients from 19 hospitals across Australia and New Zealand, treated over the last 15 years with "off-the-shelf" allogeneic T cells directed to a combination of Epstein-Barr virus (EBV), cytomegalovirus (CMV), BK polyomavirus (BKV), John Cunningham virus (JCV) and/or adenovirus (AdV) under the Australian Therapeutic Goods Administration's Special Access Scheme. Most patients had severe post-transplant viral complications, including drug-resistant end-organ CMV disease, BKV-associated haemorrhagic cystitis and EBV-driven post-transplant lymphoproliferative disorder. Adoptive immunotherapy is well tolerated with few adverse effects. Importantly, 46/71 (65%) patients show definitive clinical improvement including reduction in viral load, clinical symptoms and complete resolution of end-organ disease. In addition, seven high-risk patients remain disease free. Based on this long-term encouraging clinical experience, we propose that a dedicated nationally funded centre for anti-viral cellular therapies should be considered to provide T cell therapies for critically ill patients for compassionate use.
Publisher: Springer Nature
Keywords: Humans; *Immunotherapy, Adoptive/methods/adverse effects; *T-Lymphocytes/immunology/transplantation; Male; Female; Retrospective Studies; Middle Aged; Adult; Compassionate Use Trials; Aged; Australia; New Zealand; Young Adult; Viral Load; Virus Diseases/immunology/therapy; Immunocompromised Host; BK Virus/immunology; Adolescent; Herpesvirus 4, Human/immunology
Department(s): Haematology
Publisher's Version: https://doi.org/10.1038/s41467-024-54595-2
Open Access at Publisher's Site: https://doi.org/10.1038/s41467-024-54595-2
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2025-01-07 06:16:17

Last Modified: 2025-01-07 06:21:14